Three trials worth keeping an eye on, now with cleaner direct-source grounding than a registry-only read.
Indiana University: Registry-Led, and That Is Fine
The cleanest direct source here is still the ClinicalTrials.gov record for NCT07499583. Indiana University has posted a not yet recruiting phase 1/2 trial of psilocybin-assisted psychotherapy for treatment-resistant depression with co-occurring substance use disorder in veterans and first responders.
According to the registry, the study is aiming for 50 participants, compares 5 mg, 10 mg, and 25 mg psilocybin doses, and is designed as a randomized, double-blind trial. The record says participants will receive preparatory psychotherapy, a single dosing session, integration work, ecological momentary assessment, and pre/post imaging, with an estimated study start of August 2026.
That is enough to make the protocol worth watching. And per the current guardrail, it is better to keep this subsection anchored tightly to NCT07499583 than to pad it with softer secondary framing while a cleaner IU sponsor-side page is still missing.
Johns Hopkins: OCD Study Is Active, Not Recruiting
The Hopkins OCD item now has a better direct-source spine than a bare registry link. ClinicalTrials.gov says NCT05546658 is active, not recruiting, with an estimated primary completion date of September 12, 2026. The registry describes it as an early phase 1 study testing feasibility, safety, and preliminary evidence of efficacy for psilocybin in obsessive-compulsive disorder.
The same record says participants receive two doses of psilocybin about two weeks apart, with follow-up visits extending up to six months after the final session. The official Hopkins OCD study page confirms the sponsor-side framing under the Johns Hopkins Center for Psychedelic and Consciousness Research.
The Hopkins page reads more like a participant-facing study page than a full protocol summary, so the registry remains the better source for status and design. But using both sources makes the subsection materially cleaner than treating it as just another psychedelic-news roundup item.
UC Irvine: Official Site Makes the Design Much Clearer
The UC Irvine item also sharpens once it is anchored to both the registry and the university's own trial page. NCT07226570 and UCI's official Mapping Ibogaine Neural Dynamics in Opioid Use Disorder page describe an observational study that is recruiting, expects 20 participants, and is focused on how ibogaine treatment may change brain activity and symptoms in people with moderate-to-severe opioid use disorder.
The important design point is that UCI is not administering ibogaine. Participants must already be independently scheduled to receive legal treatment at a licensed clinic outside the United States, while the university team handles MRI, MRS, EEG, questionnaires, and urine sampling across multiple study time points.
That is a much more specific setup than the looser idea that researchers are simply looking at what ibogaine does to the brain. It is an imaging-forward observational study built around people already planning to undergo treatment elsewhere.
Taken together, these three trials are worth watching for different reasons: Indiana University is testing psilocybin in a population many psychedelic trials exclude, Johns Hopkins is bringing an OCD program toward primary completion, and UC Irvine is trying to pin ibogaine's neural effects to a more structured imaging protocol.